ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

New Option For Chronic Fatigue Syndrome

The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol

Living Longer, Healthier Lives with Resveratrol

Iodine: The Forgotten Medicine

Stop Bacteria With Nature's Antibiotics

Lipoic Acid Reverses Mitochondrial Decay

Nutraceutical Update - Rhodiola

Strengthen Cell Function with Energy-Boosting Niagen

Coenzyme Q10 Helps Veterans Battle Gulf War Illness Symptoms

New Test Shows Promise in Identifying New Drugs to Treat Lyme Disease

 
Print Page
Email Article

12-center trial of Ampligen treatment for severe ME/CFS reports positive results

  [ 67 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 15, 2012


Article:
A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist Rintatolimod [Ampligen®] in severe cases of Chronic Fatigue Syndrome
– Source: PloS One, Mar 14, 2012

By David R Strayer, Daniel L Peterson, et al.

[Note: To read the full text of this landmark open access article free, click HERE and download the PDF. Rintatolimod (aka Ampligen) was designated an “Orphan Drug” for CFS by the FDA, for the purpose of this trial.]

Abstract:
Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a severely debilitating disease of unknown pathogenesis consisting of a variety of symptoms including severe fatigue.

The objective of the study was to examine the efficacy and safety of a TLR-3 agonist, rintatolimod (Poly I: C12U), in patients with debilitating CFS/ME.

Methods and Findings: A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites.

The primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET).

Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF 36).

Subjects receiving rintatolimod [Ampligen] for 40 weeks improved intra-patient placebo-adjusted exercise tolerance 21.3% (p = 0.047) from baseline in an intention-to-treat analysis.

Correction for subjects with reduced dosing compliance increased placebo-adjusted exercise tolerance improvement to 28% (p = 0.022).

• The improvement observed represents approximately twice the minimum considered medically significant by regulatory agencies.

• The rintatolimod cohort vs. placebo also reduced dependence on drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p = 0.048).

• Placebo subjects crossed-over to receive rintatolimod [Ampligen] demonstrated an intra-patient improvement in exercise tolerance performance at 24 weeks of 39% (p = 0.04). Rintatolimod at 400 mg twice weekly was generally well-tolerated.

Conclusions/Significance: Rintatolimod [Ampligen] produced objective improvement in exercise tolerance and a reduction in CFS/ME related concomitant medication usage as well as other secondary outcomes.

Trial Registration: ClinicalTrials.gov NCT00215800
 
Source: PloS One, Mar 14, 2012. Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL, Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM. Hemispherx Biopharma, Inc., Philadelphia, Pennsylvania; BCS Consulting, Philadelphia; University of the Pacific, Stockton, California; Fatigue Consultation Clinic, Salt Lake City, Utah; Center for Special Immunology, Fountain Valley, California; Hunter-Hopkins Center, Charlotte, North Carolina; Sierra Internal Medicine Associates, Incline Village, Nevada; Vanderbilt University School of Medicine, Nashville, Tennessee, USA.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Immune Support Supplements

Featured Products

FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Protecting Our Eyes Against Time-Induced Damage Protecting Our Eyes Against Time-Induced Damage
The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing